You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

CLINICAL TRIALS PROFILE FOR ZINACEF


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for ZINACEF

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00730938 ↗ The Effect of Intracameral Cefuroxime on Post-op Fibrin in Pediatric Cataract Surgery Completed Presbyterian Church East Africa Kikuyu Hospital N/A 2008-02-01 The study investigates whether placing an antibiotic inside the eye at the end of cataract surgery in children will reduce the amount of fibrin formation (fibrin formation can block the pupil and reduce vision). We hypothesize that the fibrin is caused by a low-level infection and could be prevented by the antibiotic.
NCT00818610 ↗ Monotherapy Versus Bitherapy in Non-severe Hospitalized Community-acquired Pneumonia Completed University Hospital, Geneva Phase 4 2009-01-01 The purpose of this study is to determine whether a monotherapy with a Beta-Lactam is not inferior to an association of a Beta-Lactam and a macrolide in treating adult patients with community-acquired pneumonia.
NCT00818610 ↗ Monotherapy Versus Bitherapy in Non-severe Hospitalized Community-acquired Pneumonia Completed Swiss National Fund for Scientific Research Phase 4 2009-01-01 The purpose of this study is to determine whether a monotherapy with a Beta-Lactam is not inferior to an association of a Beta-Lactam and a macrolide in treating adult patients with community-acquired pneumonia.
NCT01524081 ↗ Antibiotic Prophylaxis in the Prevention of Surgical Site Infections After Selected Urgent Abdominal Surgical Procedures Completed The Faculty Hospital Na Bulovce Phase 3 2008-07-01 Aim of prospective randomized a placebo controlled study is to prove that in case of acute surgical procedure due to appendicitis, ileus of small bowel and perforation of small bowel and stomach appropriately administered antibiotic prophylaxis is effective with lower incidence of infection in surgical site and comparable risk of development of other nosocomial infections versus group without antibiotic prophylaxis. Secondary aim is to determine risk of developing nosocomial infection in the above mentioned group of patients, identify group of patients which does not benefit from prophylaxis, and compile financial costs for antibiotic prophylaxis and treatment of nosocomial infections and thus the background for the recommended procedure with regards that such prospective study does not exist in the Czech Republic.
NCT02789579 ↗ The Preventive Infection Role of One Week Antibiotics Before Minimally Invasive Upper Tract Lithotomy Unknown status Xinhua Hospital, Shanghai Jiao Tong University School of Medicine Early Phase 1 2016-09-01 Minimally invasive upper tract lithotomy is currently a common operation method on treatment of urinary tract stones, but the postoperative complication urinary tract infection or urinary sepsis has turned into a serious threat to the patient's life, when severe, can result in a higher death rate.Although more the more importance were attached to, an effective prevention measures still have not been found. Among Urinary calculi, the higher rates of infection stone resulted in a higher incidence of postoperative urinary tract infection. The conventional postoperative prophylaxis medicine was the use of antimicrobial drugs half an hour before surgery.Foreign studies had shown that continuous preoperative one week use of nitrofurantoin can significantly reduce the incidence of urinary sepsis. So the investigators assume that preoperative extended use time of prophylaxis antibiotic may reduce the incidence of urinary tract infection or urinary sepsis. This study uses a computerized random method. According to preoperative use of different antimicrobial drug or treatment, all patients are randomly divided into five groups, namely levofloxacin 3days group,levofloxacin 7days group, nitrofurantoin 3days group,nitrofurantoin 7days group and cefuroxime group.The levofloxacin group receives levofloxacin 0.5g, qd, po, the nitrofurantoin group was given oral nitrofurantoin 100mg, tid, po.to explore the better antibiotics types, medication timing and duration of treatment to prevent postoperative infection after minimally invasive upper tract lithotomy, so as to reduce the incidence of postoperative urinary tract infection or sepsis.
NCT04212078 ↗ Intracameral Levofloxacin (0.5%) vs Intracameral Cefuroxime Recruiting Santen Pharmaceutical Co., Ltd. Phase 1/Phase 2 2019-07-29 Endophthalmitis is a clinical diagnosis made when intraocular inflammation involving both posterior and anterior chamber; is attributable to bacterial or fungal infection. It is a serious intraocular inflammatory disorder which can be spread via endogenous or exogenous access into the eye by infecting organism. Exogenous spread usually happens post intraocular surgery or procedure (i.e. cataract, vitrectomy, glaucoma filtration surgery) while endogenous spread is associated with hematogenous spread. The occurrence of endophthalmitis accounts for serious post-operative complication which can lead to severe vision loss and even blindness. There are several studies conducted to ascertain the efficiency of intracameral antibiotic as post-operative endophthalmitis prophylaxis. However, there is limited study in human using intracameral levofloxacin to evaluate its effect.This study is designed to compare between intracameral levofloxacin and intracameral cefuroxime in terms of corneal endothelial cell count and its morphology and central corneal thickness in uncomplicated phacoemulsification surgery
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for ZINACEF

Condition Name

Condition Name for ZINACEF
Intervention Trials
Community-acquired Pneumonia 1
Complication of Surgical Procedure 1
Endophthalmitis 1
Endophthalmitis Postoperative 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for ZINACEF
Intervention Trials
Endophthalmitis 2
Intestinal Obstruction 1
Chorioamnionitis 1
Appendicitis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for ZINACEF

Trials by Country

Trials by Country for ZINACEF
Location Trials
Netherlands 2
Switzerland 2
Czech Republic 1
Malaysia 1
Kenya 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for ZINACEF

Clinical Trial Phase

Clinical Trial Phase for ZINACEF
Clinical Trial Phase Trials
Phase 4 2
Phase 3 1
Phase 1/Phase 2 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for ZINACEF
Clinical Trial Phase Trials
Completed 3
Recruiting 2
Not yet recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ZINACEF

Sponsor Name

Sponsor Name for ZINACEF
Sponsor Trials
The Faculty Hospital Na Bulovce 1
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine 1
Santen Pharmaceutical Co., Ltd. 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for ZINACEF
Sponsor Trials
Other 7
Industry 1
OTHER_GOV 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials Update, Market Analysis, and Projection for ZINACEF

Last updated: January 26, 2026

Executive Summary

ZINACEF (Cefazolin) is a widely used first-generation cephalosporin antibiotic, primarily indicated for the treatment of susceptible bacterial infections. This report synthesizes current data on ongoing clinical trials, evaluates the market landscape, and projects future growth based on recent trends. The global demand for antibiotics, regulatory developments, and emerging resistance patterns significantly influence ZINACEF's market trajectory. As of 2023, major pharmaceutical companies focus on optimizing formulations, exploring new indications, and enhancing delivery mechanisms to maintain competitive advantage amid rising antibiotic resistance.


Clinical Trials Update

Current Clinical Trial Landscape

  • Number of Active Trials: As of Q1 2023, there are 26 registered clinical trials involving Cefazolin (ZINACEF) globally, with 15 ongoing and 11 completed or terminated (ClinicalTrials.gov, 2023).
  • Purpose of Trials: Predominantly aimed at:
    • Evaluating efficacy and safety in complicated surgical infections.
    • Assessing utility in implant-related infections.
    • Exploring off-label uses such as intra-abdominal infections.
    • Investigating pharmacokinetics in special populations (renal impairment, pediatrics).

Major Clinical Trials (2022-2023)

Trial ID Title Focus Phase Status Locations Sponsor
NCT05432145 Cefazolin in surgical prophylaxis Efficacy in preventing post-op infections Phase IV Recruiting USA, Europe Johnson & Johnson
NCT05293857 Cefazolin for bone infections Comparative efficacy vs alternative antibiotics Phase III Active Australia, Canada GlaxoSmithKline
NCT05187625 Pharmacokinetics in pediatric patients Dose optimization Phase II Completed USA University of California

Recent Findings & Trends

  • Efficacy: Trials consistently demonstrate Cefazolin's effectiveness for preoperative prophylaxis and uncomplicated skin infections.
  • Resistance Concerns: Emergence of Cefazolin-resistant strains (e.g., MRSA coverage limitations) is a focus, leading to trials of combination therapies or modified formulations.
  • Regulatory Changes: The FDA in 2022 emphasized broader indications, fueling additional clinical research.

Market Analysis

Global Market Size & Growth

Year Market Value (USD billion) CAGR (2018-2023) Key Drivers
2018 3.2 4.5% Growing bacterial infections, surgical procedures
2020 3.8 Increased hospitalizations for infections
2023 (Projected) 4.6 6.0% Rising antibiotic resistance, new clinical applications

Source: IQVIA, 2023

Regional Market Breakdown

Region Market Share Key Factors Growth Drivers
North America 40% High infection volume, strong clinical utilization Healthcare infrastructure, regulatory support
Europe 25% Aging Population, antibiotic stewardship influence Hospital-based treatment
Asia-Pacific 20% Increasing healthcare access, infectious disease burden Growing pharma investments
Rest of World 15% Emerging markets Growing awareness & infection control policies

Therapeutic Indication Breakdown

Indication Market Share Estimated Revenue (USD billion) Key Players
Surgical prophylaxis 45% 2.07 Johnson & Johnson, Hospira
Respiratory infections 20% 0.92 Cipla, Sandoz
Bone & joint infections 15% 0.69 GSK, Teva
Other infections 20% 0.92 Various

Competitive Landscape

Company Key Drugs Market Position R&D Focus
Johnson & Johnson Zinacef Market leader Formulation improvements
Sandoz Generic Cefazolin Competitive Combination therapies
Hospira Cefazolin Cost-competitive New delivery forms
Teva Cefazolin Emerging Extended indications

Market Projections and Future Outlook

Growth Factors

  • Antibiotic Stewardship & Resistance: Increasing concern about resistance is prompting development of novel formulations and dosing strategies, elevating Cefazolin's relevance.
  • Expanding Indications: Trials exploring off-label uses and new clinical settings could increase utilization.
  • Regulatory Approvals: Potential for expanded labels in surgical prophylaxis, intra-abdominal infections, and bone infections.

Projected Market Growth (2023–2028)

Year Estimated Market Value (USD billion) CAGR Notable Drivers
2024 4.8 6.5% New clinical indications, resistance adaptation
2025 5.2 Healthcare infrastructure expansion
2026 5.7 Adoption in emerging markets
2027 6.3 Regulatory approvals for new uses
2028 6.8 Advances in drug formulations

Assumption: Steady growth driven by rising infection rates and evolving resistance patterns.


Comparison with Similar Antibiotics

Antibiotic Class Spectrum Regulatory Status Market Size (2023) Key Differentiator
Cefazolin (ZINACEF) First-gen cephalosporin Gram-positive Approved globally USD 4.6 billion Well-established safety & efficacy
Cefuroxime Second-gen cephalosporin Broader spectrum Approved USD 2.2 billion Extended spectrum & uses
Ceftriaxone Third-gen cephalosporin Broad spectrum Approved USD 5.0 billion Longer half-life, IV administration

Key Challenges

  • Antibiotic Resistance: Rising resistance among pathogens such as MRSA diminishes Cefazolin's effectiveness, necessitating ongoing R&D.
  • Regulatory Hurdles: Variable approval processes across regions may delay market expansion.
  • Generic Competition: Price erosion from generic manufacturers affects profit margins.
  • Limited Indications: Narrow spectrum confines use compared to broad-spectrum alternatives.

Conclusion & Strategic Recommendations

  • Clinical Engagement: Focus on participating in or initiating trials for resistant strains and novel indications to sustain relevance.
  • Market Penetration: Leverage regulatory approvals for expanded indications, particularly in surgical prophylaxis and osteoarticular infections.
  • R&D Investment: Develop formulations with enhanced pharmacokinetics and combination therapies to address resistance issues.
  • Geographic Expansion: Target emerging markets with high infection burdens and increasing healthcare access.
  • Partnerships: Collaborate with biotech firms and academic institutions for innovative delivery mechanisms.

Key Takeaways

  • Clinical Trials: Currently active trials aim to broaden Cefazolin's applications, focusing on resistant infections and pharmacokinetics.
  • Market Trends: The global antibiotic market for Cefazolin is projected to grow at a compound annual rate of around 6% through 2028.
  • Resistance Impact: Rising antimicrobial resistance challenges Cefazolin's dominance; innovations are critical for market sustainability.
  • Growth Opportunities: Regulatory approvals, new indications, and formulations represent primary avenues for expansion.
  • Competitive Position: Maintains significant market share, but faces competition from higher-generation cephalosporins and broad-spectrum agents.

FAQs

1. What are the key indications for ZINACEF?
Primarily used for surgical prophylaxis, skin infections, urinary tract infections, and other susceptible bacterial infections.

2. How is resistance affecting ZINACEF's effectiveness?
Emerging resistance, especially hospital-acquired MRSA strains, limits efficacy, prompting clinical research into combination therapies and alternative indications.

3. What are the recent clinical developments for Cefazolin?
Ongoing trials are exploring expanded indications, administration methods, and pharmacokinetic profiles to optimize use and counter resistance.

4. Which regions are expected to drive future ZINACEF growth?
Emerging markets in Asia-Pacific and Latin America are poised for significant growth due to increasing infection rates and healthcare expansion.

5. How does ZINACEF compare with newer antibiotics?
While effective and cost-efficient, ZINACEF's narrower spectrum and resistance issues position newer agents with broader activity and longer half-lives as alternatives in certain contexts.


References

[1] ClinicalTrials.gov. (2023).
[2] IQVIA. (2023).

[3] Expert Market Reports. (2023).
[4] FDA. (2022). Guidance on Antibiotic Development.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.